News

Christopher Strafaci joins as VP Sales & Marketing, North America

RenalSense welcomes Christopher Strafaci as VP Sales & Marketing, North America. Chris joins us after his most recent sales management position at Cogentix Medical, where he headed the endoscopy business unit with double-digit quarterly sales increases. The company was acquired by Laborie Medical Technologies, where Chris continued this leadership role.

RenalSense awarded 3 million NIS grant for medical innovation

RenalSense is one of three Israeli medtech companies that were recently awarded funding grants from the Israel Innovation Authority and the Israeli Ministry of Economy and Industry. The company received 3 million NIS for development of its second generation system.

RenalSense to present at MedCity INVEST

RenalSense will be making a presentation at the “Pitch Perfect Startup Contest” at MedCity INVEST, to be held April 23-24 in Chicago. MedCity INVEST is a leading national healthcare investing conference uniting active investors with corporate business development executives to facilitate investment opportunities with the most promising healthcare startups.

RenalSense sponsors industry symposium at AKI&CRRT 2019 meeting

As part of the 2019 AKI&CRRT meeting in San Diego, RenalSense sponsored a symposium entitled “Urine Flow Rate and its Use as a Biomarker in Critical Care.” The speakers were Professor John Kellum, Director of the Center for Critical Care Nephrology at the University of Pittsburgh, and Professor Robert Safirstein of the Department of Medicine (Nephrology) at Yale University. The presentations covered the potential of urine flow as an early indicator of AKI, and as a real-time parameter for response to therapy, and for local and systemic disease. Watch video of Kellum lecture.

RenalSense participates in Israeli industry delegation to China

In mid-December, RenalSense participated in an Israeli industry delegation to China, consisting of 26 companies selected by the China-Israel Joint Committee on Innovation Cooperation. As a member of the delegation, we conducted a speaking tour in Changzhou, Shenzhen, Shanghai and Beijing, to promote joint innovation and collaboration between the two countries.

Renalsense announces pilot study at University of Pittsburgh Medical Center

RenalSense® announced today that it is conducting a pilot study with its Clarity RMS® critical care monitoring system at the University of Pittsburgh Medical Center (UPMC), under the direction of Professor John Kellum. See Press Release.

RenalSense to represent Israel at International Entrepreneurship Competition in China

RenalSense is proud to announce that it was selected as one of five companies to represent Israel at the Xi’an International Entrepreneurship Competition for outstanding global innovation this December. The competition, sponsored by the Xi’an Municipal Government, includes startups in the fields of IT, bio-med, advanced manufacturing and new materials from Silicon Valley, Berlin, London, Brisbane, and Tel Aviv, as well as from six regions in China.

RenalSense Announces Distribution Agreement With Fresenius Medical Care

RenalSense® has entered into an agreement with Fresenius Medical Care (Bad Homburg) for distribution of its Clarity RMS critical care urine monitoring system in Europe, the Middle East, and Africa (EMEA). Fresenius Medical Care will market the company’s products in 85 EMEA countries through its acute care division. See Press Release.

RenalSense to present at ASN Kidney Week 2017

RenalSense will be participating in the upcoming ASN Kidney Week 2017 Annual Meeting, to be held Oct 31st – Nov 5th in New Orleans.

​The company will present a scientific poster entitled “Identification of the Oliguric Patient Using a Novel Electronic Device for Measuring Urine Output” on Thursday Nov 2nd in the 10:00 am Poster Session on AKI. The company will also ​be exhibiting at ​Booth ​#514, where visitors will have the opportunity to meet with members of the senior management team.

RenalSense publishes scientific paper

RenalSense published its first full-length article in the September issue of “Clinical Medicine Insights: Trauma and Intensive Medicine”. 

The article describes the company’s recent clinical trial conducted in the ICU at Jerusalem’s Hadassah Hospital.

RenalSense installs Clarity RMS at Mt. Sinai in NY

RenalSense installed its first Clarity RMS Urine Monitoring System in the surgical ICU at New York’s Mt. Sinai West (formerly Roosevelt Hospital), under the supervision of Professor Hassan Khouli.

RenalSense to present at AKI&CRRT 2017

RenalSense will be participating in the upcoming AKI&CRRT 2017 – The 22 nd International Conference on Advances in Critical Care Nephrology – Updates in ICU Medicine: Controversies, Challenges, and Solutions, to be held March 7th-10th in San Diego.

Dr. Mor Grinstein, Co-Founder and Chief Medical Officer, will be making an oral presentation entitled “A Novel Electronic Device for Measuring Urine Flow Rate” on Wednesday March 8 th in the 6:00 PM session on Clinical Research in AKI and NAP.

The company will also have an exhibition booth at the conference, where visitors will have the opportunity to meet with members of the senior management team.

RenalSense selected to present to Biomed Investors Group

RenalSense was selected as one of five companies to present at the JLM-Biocity Biomed Startup Pitch Evening held on December 20th in Jerusalem.  JLM-Biocity is a private initiative of 900 bio entrepreneurs, professionals and businesspeople seeking to make Jerusalem a global life science innovation leader. The presentation was made to a panel of investors, VC funds, and global companies.

RenalSense presents clinical data at Annual ASN Congress

RenalSense’s clinical team presented a scientific poster at Kidney Week of the American Society of Nephrology (ASN) 2016 in Chicago. The poster summarized the findings of the company’s recent prospective trial with 40 ICU patients at Hadassah Hospital in Jerusalem, Israel. See the abstract.